E.G. Nesukay Stable angina pectoris treatment in Ukraine: CLASSICA trial

144 cardiologists from 34 regions of Ukraine took part in the trial “The most effective combination of antianginal medications in treatment of patients with stable angina pectoris” (CLASSICA). We analyzed 1423 ambulatory cards of patients with stable angina pectoris and showed that the studied population included the patients of very high cardiovascular risk, often with large duration of IHD and its complications, with different concomitant pathology, unsatisfactory control of symptoms of angina and cardiovascular risk. Trimetazidine MR substantially diminished number of angina attacks and consumption of short acting nitrates in patients on a background treatment by beta-receptor blockers or in combination with long acting nitrates or calcium channel blockers. The combined usage of long-acting nitrates or calcium channel blockers with beta-receptor blockers does not result in the additional decrease of frequency of angina attacks per week as compared to patients receiving betareceptor blockers and trimetazidine MR. As a metabolic agent without influence on hemodynamic parameters, trimetazidine MR can be used in combination for treatment of stable angina pectoris providing high antiischemic and antianginal efficacy in patients with stable angina pectoris.

Full article